368 related articles for article (PubMed ID: 21282338)
41. Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.
Hornig N; Reinhardt K; Kermer V; Kontermann RE; Müller D
Cancer Immunol Immunother; 2013 Aug; 62(8):1369-80. PubMed ID: 23715927
[TBL] [Abstract][Full Text] [Related]
42. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
43. The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFN gamma.
Arina A; Murillo O; Hervás-Stubbs S; Azpilikueta A; Dubrot J; Tirapu I; Huarte E; Alfaro C; Pérez-Gracia JL; González-Aseguinolaza G; Sarobe P; Lasarte JJ; Jamieson A; Prieto J; Raulet DH; Melero I
Int J Cancer; 2007 Sep; 121(6):1282-95. PubMed ID: 17520674
[TBL] [Abstract][Full Text] [Related]
44. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Front Immunol; 2020; 11():40. PubMed ID: 32082316
[TBL] [Abstract][Full Text] [Related]
45. Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.
Fernández L; Metais JY; Escudero A; Vela M; Valentín J; Vallcorba I; Leivas A; Torres J; Valeri A; Patiño-García A; Martínez J; Leung W; Pérez-Martínez A
Clin Cancer Res; 2017 Oct; 23(19):5824-5835. PubMed ID: 28659311
[No Abstract] [Full Text] [Related]
46. Construction and evaluation of a novel humanized HER2-specific chimeric receptor.
Sun M; Shi H; Liu C; Liu J; Liu X; Sun Y
Breast Cancer Res; 2014 Jun; 16(3):R61. PubMed ID: 24919843
[TBL] [Abstract][Full Text] [Related]
47. Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation.
Zhou S; Meng F; Du S; Qian H; Ding N; Sha H; Zhu M; Yu X; Wang L; Liu B; Wei J
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986122
[TBL] [Abstract][Full Text] [Related]
48. Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system.
Lazarova M; Wels WS; Steinle A
Expert Opin Biol Ther; 2020 Dec; 20(12):1491-1501. PubMed ID: 32726145
[TBL] [Abstract][Full Text] [Related]
49. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
[TBL] [Abstract][Full Text] [Related]
50. T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice.
VanSeggelen H; Hammill JA; Dvorkin-Gheva A; Tantalo DG; Kwiecien JM; Denisova GF; Rabinovich B; Wan Y; Bramson JL
Mol Ther; 2015 Oct; 23(10):1600-10. PubMed ID: 26122933
[TBL] [Abstract][Full Text] [Related]
51. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.
Pievani A; Borleri G; Pende D; Moretta L; Rambaldi A; Golay J; Introna M
Blood; 2011 Sep; 118(12):3301-10. PubMed ID: 21821703
[TBL] [Abstract][Full Text] [Related]
52. NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease.
Hanaoka N; Jabri B; Dai Z; Ciszewski C; Stevens AM; Yee C; Nakakuma H; Spies T; Groh V
J Immunol; 2010 Nov; 185(10):5732-42. PubMed ID: 20926796
[TBL] [Abstract][Full Text] [Related]
53. The natural killer-activating receptor, NKG2D, on CD3+CD8+ T cells plays a critical role in identifying and killing autologous myeloma cells.
Talebian L; Fischer DA; Wu J; Channon JY; Sentman CL; Ernstoff MS; Meehan KR
Transfusion; 2014 Jun; 54(6):1515-21. PubMed ID: 24446786
[TBL] [Abstract][Full Text] [Related]
54. B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity.
Wu MR; Zhang T; Gacerez AT; Coupet TA; DeMars LR; Sentman CL
J Immunol; 2015 Jun; 194(11):5305-11. PubMed ID: 25911747
[TBL] [Abstract][Full Text] [Related]
55. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
56. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
Jiang W; Zhang C; Tian Z; Zhang J
Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
[TBL] [Abstract][Full Text] [Related]
57. Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection.
Deng W; Gowen BG; Zhang L; Wang L; Lau S; Iannello A; Xu J; Rovis TL; Xiong N; Raulet DH
Science; 2015 Apr; 348(6230):136-9. PubMed ID: 25745066
[TBL] [Abstract][Full Text] [Related]
58. Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer.
Zhang Y; Liang K; Zhou X; Zhang X; Xu H; Dai H; Song X; Yang X; Liu B; Shi T; Wei J
Cancer Sci; 2023 Jul; 114(7):2798-2809. PubMed ID: 37151176
[TBL] [Abstract][Full Text] [Related]
59. A new recombinant single chain trispecific antibody recruits T lymphocytes to kill CEA (carcinoma embryonic antigen) positive tumor cells in vitro efficiently.
Wang XB; Zhao BF; Zhao Q; Piao JH; Liu J; Lin Q; Huang HL
J Biochem; 2004 Apr; 135(4):555-65. PubMed ID: 15115782
[TBL] [Abstract][Full Text] [Related]
60. NKG2D CARs as cell therapy for cancer.
Sentman CL; Meehan KR
Cancer J; 2014; 20(2):156-9. PubMed ID: 24667963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]